Skip to main content
OpenTrials
Completed

NCT Number: NCT05634005

Clinical Decision Support for Blood Transfusions to Improve Guideline Adherence

Determine whether clinical decision support (best practice advisory) improves provider adherence to transfusion guidelines for all four major blood components (red blood cells, plasma, platelets, and cryoprecipitate) using a randomized study design to reduce risk of bias. Alerts will be visible to the experimental ordering provider group, while they will not be visible to the control. Both groups still have access to information about best practices: local clinical transfusion guidelines are available and education on blood transfusion best practices will continue regardless of randomization assignment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anemia Afibrinogenemia Blood Coagulation Disorders Blood Coagulation Disorders, Inherited Blood Platelet Disorders Cardiovascular Diseases Coagulation Protein Disorders Coagulopathy, Mild Congenital, Hereditary, and Neonatal Diseases and Abnormalities Cytopenia Genetic Diseases, Inborn Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Hypofibrinogenemia Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Thrombocytopenia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Utah

Salt Lake City, Utah, 84132, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ordering providers that order at least one blood product in the electronic health record

Exclusion criteria

  • Any individual without privileges to place an initial order for blood product(s)

Treatment and study plan

Clinical Decision Support

Behavioral

In blood product order entry within the electronic health record, the ordering provider is required to select an indication for the blood product order. If the patient's laboratory values are not in line with the guideline indication selected, a clinical decision support alert will fire and be shown to the ordering provider. This alert will inform the provider that the order is outside institutional guidelines and the provider has the option to cancel the order (or bypass the order and select a reason for proceeding with the order).

Other names: Best Practice Advisory

Primary outcomes

  1. Number of blood components transfused that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of blood components transfused (includes red blood cell, platelet, plasma, and cryoprecipitate pools) that met criteria for clinical decision support alerts to fire

Secondary outcomes

  1. Number of red blood cell components transfused that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of red blood cell components transfused that met criteria for clinical decision support alerts to fire

  2. Number of platelet components transfused that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of platelet components transfused that met criteria for clinical decision support alerts to fire

  3. Number of plasma components transfused that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of plasma components transfused that met criteria for clinical decision support alerts to fire

  4. Number of cryoprecipitate component pools transfused that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of cryoprecipitate component pools transfused that met criteria for clinical decision support alerts to fire

Other outcomes

  1. Number of blood components ordered that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of blood components ordered (includes red blood cell, platelet, plasma, and cryoprecipitate pools) that met criteria for clinical decision support alerts to fire

  2. Number of red blood cell components ordered that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of red blood cell components ordered that met criteria for clinical decision support alerts to fire

  3. Number of platelet components ordered that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of platelet components ordered that met criteria for clinical decision support alerts to fire

  4. Number of plasma components ordered that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of plasma components ordered that met criteria for clinical decision support alerts to fire

  5. Number of cryoprecipitate component pools ordered that met clinical decision support alert criteria

    Time frame: Through study completion, an average of 12 months

    Number of cryoprecipitate component pools ordered that met criteria for clinical decision support alerts to fire

  6. Number of blood components transfused

    Time frame: Through study completion, an average of 12 months

    Number of blood components transfused (includes red blood cell, platelet, plasma, and cryoprecipitate pools) that met criteria for clinical decision support alerts to fire

  7. Number of red blood cell components transfused

    Time frame: Through study completion, an average of 12 months

    Number of red blood cell components transfused

  8. Number of platelet components transfused

    Time frame: Through study completion, an average of 12 months

    Number of platelet components transfused

  9. Number of plasma components transfused

    Time frame: Through study completion, an average of 12 months

    Number of plasma components transfused

  10. Number of cryoprecipitate component pools transfused

    Time frame: Through study completion, an average of 12 months

    Number of cryoprecipitate component pools transfused

  11. Blood component cost difference between clinical decision support eligible transfusions by study arm

    Time frame: Through study completion, an average of 12 months

    Blood component acquisition cost difference of completed alert eligible transfusions between study arms

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Dec 1, 2022
Registry last updated
Mar 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.